Sangamo Therapeutics (SGMO) Misses Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Oil surge keeps S&P 500, Nasdaq in check before earnings; Salesforce lifts Dow
- Oil prices rise as attacks on Saudi Arabia overshadow Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts SGMO Hot Sheet
Join SI Premium – FREE
Sangamo Therapeutics (NASDAQ: SGMO) reported Q4 EPS of ($0.34), $0.08 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $2.04 million versus the consensus estimate of $8.11 million.
For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Can broadening earnings growth sustain the equity upcycle? JPM weighs in
- Citi maintains buy rating on JD.com with $39 price target
- Destra Multi-Alternative Fund launches buyback, raises distribution
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
